OBJECTIVE: To report the anatomical and functional results of intravitreal injections of aflibercept (Eylea) (A-IVI) for the treatment of na  ve eyes with neovascular age-related @entity1020 (nv- @entity13785 ). SUBJECTS AND METHODS: This retrospective, one-center, non-comparative chart review included 26 treatment na  ve eyes with nv- @entity13785 of 26 @entity1 (14 male) with a mean age of 80.5 (range 63-91) who had a complete follow-up of 14 months. The morphological analysis included spectral domain optical coherence tomography and fundus @entity941 angiography, while the functional assessment included logarithm of the minimum angle of resolution (LogMAR) best correct visual acuity (BCVA). The timing of the follow-up was: baseline, 3, 6, and 14 months. All @entity1 received 8 A-IVI according to the protocol (first 3 consecutive monthly A-IVI, followed by bi-monthly retreatment for the first year, regardless of disease activity as per local guidelines). Statistical analysis was performed using ANOVA. Improvement of visual acuity more than 15 letters was considered as "improvement", less than 5 letters as "stable" and any letter loss as "worsening". RESULTS: Mean  standard deviation LogMAR visual acuity improved from 0.26  0.15 at presentation to 0.14  0.20 at the final follow-up of 14 months (P=0.02). BCVA was stable in 23.1%, improved in 61.5% (16 eyes) worsened in 15.4%. A mean pretreatment central macular thickness of 409 m reduced significantly to 229 m at month 14 (P<0.02). The OCT of eyes with worsened BCVA showed resolution of retinal fluid but presence of subretinal @entity82 . No adverse events were attributed to aflibercept. CONCLUSIONS: @entity1 who had a worsening in visual acuity were found to have longer duration of symptoms prior to treatment and presence of @entity10691 , and/or subretinal @entity548 and/or subretinal @entity82 at baseline. From our experience, with 14 months follow-up, A-IVI is an effective treatment for treatment na  ve @entity1 with nv- @entity13785 . Our real world results were similar to pivotal trials.

Intravitreal aflibercept (A-IVI) for the treatment of neovascular age-related XXXX (nv- @entity13785 ): one year experience.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhage'] @entity10691 :: ('MESH:D057092', 'Disease') :: ['geographic atrophy'] @entity13785 :: ('MESH:D006009', 'Disease') :: ['AMD'] @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['macular degeneration']
@entity1020 :: (MESH:D008268,Disease) :: ['macular degeneration']
